Nefiracetam is being studied as a novel cognition-enhancing agent; however, it has been suggested from studying its chemical structure that it has a potential anticonvulsive effect. We examined the antiepileptic effect of nefiracetam on kainic acid 
Introduction
Nefiracetam (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl) acetamide, is a pyrrolidone derivative and a cyclic analogue of gamma-aminobutyric acid (GABA).
Both piracetam and levetiracetam are also pyrrolidone derivatives and have a similar chemical structure of nefiracetam. Piracetam has been used in some countries to treat mental disorders (Croisile et al., 1993, Richardson and Bereen, 1977) . This drug has an antiepileptic effect and was indicated as add-on therapy for myoclonus (Obeso et al., 1988) . A ethyl analogue of piracetam, levetiracetam, is effective in audiogenic, maximal electroshock, chemoshock and amygdala-kindled seizure models (Gower et al., 1992 , Loscher and Honack, 1993 , Loscher et al., 1998 . Levetiracetam showed an antiepileptic effect in patients with complex partial seizures (Singh et al., 1992) , and clinical studies are going on in Europe.
At first, Nefiracetam as a novel cognition-enhancing agent attracted the attention of pharmacologists (Sakurai et al., 1989) . This drug improved the learning and memory functions in several experimental amnesia models and is currently undergoing experimental and clinical studies (Sakurai et al., 1990 , Nabeshima et al., 1991 , Luthman et al., 1992 , Watabe et al., 1993 , Abe et al., 1994 , Gouliaev and Senning, 1994 , Yoshii and Watabe, 1994 , Huang et al., 1996 , Yoshii et al., 1997 , Nishizaki et al., 1998 , Sakurai K. HASHIZUME 4 et al., 1998 . However, from its chemical structure, it seemed possible that nefiracetam had a potential anticonvulsive effect like piracetam and levetiracetam. In fact, nefiracetam inhibited maximal electroshock seizures in rats (Kitano et al., 1994) . The maximal electroshock seizure may be a model of acute convulsion rather than an epilepsy model. Antiepileptic effect should be studied on various models. The aim of this study is to examine the antiepileptic effect of nefiracetam on kainic acid (KA)-induced seizures.
Material and Methods

KA-induced seizure model and treatment using nefiracetam
Twenty-five male Wistar rats weighing 250-380 g were used to study the electrographic and clinical effects of KA-induced seizures. The animals were immobilized on a stereotaxic apparatus under intraperitoneal pentobarbital anesthesia. A stainless steel tube, 0.6 mm in outer diameter and 20 mm in length, was prepared as an injection guide cannula. Bipolar depth electrodes were made with twisted Teflon-coated stainless steel wires (0.2 mm in diameter and 60mm in length). The cannula was fixed to the electrode by a adhesive, and a combined cannula/electrode was inserted into the left basolateral amygdaloid nucleus (A: +5.0, L: +5.0, D: -3.0) in accordance with the information provided in the atlas of Pellegrino, et al (1979) . The bipolar depth electrodes were also inserted into the right amygdala (A: +5.0, L: -5.0, D: -3.0) and bilateral hippocampus (A: +3.0, L: +/-3.2, D: +1.5) for recording EEGs. The electrodes were connected with a socket, and the cannula, electrodes and socket were fixed to the skull with dental resin cement. The rats were kept for 7 days to allow recovery from the surgical damage. To prepare a KA solution, KA (Sigma, 1.0 mg) was dissolved in a phosphate buffer solution (0.2 M, pH 7.4, 1.0 ml). Seven days after the surgery, 1.0 μl of the KA solution was infused into the left amygdala via the cannula at a rate of less than 0.2 μl/min. EEG and behavior were recorded by a video-monitoring system. While in a limbic seizure status (60 to 100 minutes after KA infusion), 10, 50, 100 or 200 mg/kg of nefiracetam (Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan), which had been dissolved in a physiological saline (10 mg/ml), was intravenously injected via a tail vein in 19 animals (2 with 10 mg/kg, 3 with 50 mg/kg, 6 with 100 mg/kg and 8 with 200 mg/kg). For the control group of 6 rats, 1.0 ml of physiological saline was injected via the same route. Following the intravenous injection of nefiracetam or physiological saline, EEGs and behavior were recorded continuously for 8 hours, then intermittently after 24, 48 and 72 hours. The animals were decapitated as soon as the last blood sample was collected. The brains were removed quickly, frozen instantly at -20℃, then serially sliced to 20 μm-thick coronal sections in a cryostat. The sections were dried immediately at 60℃. Medical Co., Tokyo, Japan). Local cerebral glucose utilization (LCGU) was computed according to the equation described by Sokoloff, et al. (1977) . LCGU in the brain structures was averaged over 2 consecutive slices (to reduce any error due to slice thickness) and comparatively analyzed by employing the Mann-Whitney U-test.
Results
Clinical and electrophysiological effects of nefiracetam
Continuous low-amplitude polyspikes were induced in the left amygdala by KA. The seizure activity developed into rhythmic spikes and propagated to the ipsilateral hippocampus and contralateral amygdala and hippocampus. Simultaneously, clinical seizures were observed as searching, motion arrest, hypersalivation and facial twitching.
Soon these seizure activities appeared once in 5 to 10 minutes and developed into a limbic seizure at 60 to 100 minutes after KA infusion. The limbic seizures status and EEG change were seen in all animals.
During the seizure status, intravenous nefiracetam at a dose of 10 (in two rats) or 50 mg/kg (in three) caused no behavioral or EEG changes. However, when a dose of 100 mg/kg was administered, the animals became sedated immediately. The six rats that regions compared to our data of normal animals , Hashizume et al., 1998a , 1998b : bilateral amygdala, hippocampus and other limbic structures, left caudate-putamen, thalamus, substantia nigra, and sensorimotor cortex. These metabolic changes were similar to the previous report described by Tanaka et al. (1990) Table 1 . The data were compared between nefiracetam-treated and just KA-treated on the same side.
Discussions
It is well known that KA is a potent neuroexcitatory agent and its systemic or local administration induces epileptic seizures in experimental animals (Ben-Ari et al., 1979 , Lothman and Collins, 1981 , Olney, 1981 , Sperk et al., 1983 , Berger et al., 1986 , K. HASHIZUME 10 Clifford et al., 1990 . In rats and cats, a microinjection of KA into the unilateral amygdala induced limbic seizures in the acute stage and spontaneous limbic or secondarily generalized seizures in the chronic stage (Tanaka et al., 1988 ). These experimental seizures were similar to those caused by human temporal lobe epilepsy (Tanaka et al., 1992) . KA-induced amygdaloid seizures are very severe. According to previous studies, the only antiepileptic that was capable of suppressing these seizures was zonisamide (Takano et al., 1995) . However, it appeared that nefiracetam reduced limbic seizures when applied in dosages over 100 mg/kg. Clinical seizures were suppressed with 100 mg/kg of nefiracetam and the rats remained sedated in spite of exposure to a noxious stimulus. However, electrographic seizure activities persisted.
When 200 mg/kg of nefiracetam was injected, both clinical and the electrically observed seizures disappeared; and an anesthetic effect was also observed. In the study of single oral dose toxicity of nefiracetam, LD50 value was 1200-1400 mg/kg in rats (Sugawara et al., 1994) . Thus, 200 mg/kg of intravenous dose was relatively high but not toxic. Kitano et al. (1994) observed that over 60 mg/kg oral dose of nefiracetam decreased in alertness. From the change in glucose metabolism, it was found that nefiracetam dose-dependently suppresses propagation of areas of seizure-related hypermetabolism.
These results suggested that the mechanism by which nefiracetam exerts its K. HASHIZUME 11 antiepileptic effect might be based on a reduction of seizure propagation. Additionally, nefiracetam reduced the neocortical glucose metabolism as compared with the normal animals. The results also indicated the affinity of nefiracetam to the neocortex, however, no receptors for this agent have been identified. The synaptic plasma membrane is a possible binding site of levetitacetam in antiepileptic effect (Noyer et al., 1995) .
In the studies on a cognition-enhancing mechanism, it has been reported that nefiracetam facilitates cholinergic, GABAergic and monoaminergic neurotransmissions (Nabeshima et al., 1991 , Luthman et al., 1992 , Watabe et al., 1993 , Abe et al., 1994 , Yoshii and Watabe, 1994 , Huang et al., 1996 , Yoshii et al., 1997 , Nishizaki et al., 1998 .
The dose-response curves of GABA-induced current were bell-shaped. Nefiracetam caused the GABA-evoked chloride currents at a low concentration of GABA to increase and caused a reduction at a high concentration (Huang et al., 1996) . The submicromolar concentration of nefiracetam decreased acetylcholine-evoked currents and the micromolar concentration enhanced them (Nishizaki et al., 1998) . It was suggested that these effects were caused by the regulation of protein kinase A, C and G-protein.
However, the exact biochemical mechanism by which nefiracetam acts has not been elucidated.
In the present study, it was indicated that nefiracetam has a marked antiepileptic K. HASHIZUME 12 effect and that its application may suppress seizure propagation. Further study is required to elucidate the antiepileptic mechanism and biochemical characteristics of nefiracetam and whether this agent is available as a novel anticonvulsant. 
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